ABT-418

ABT-418

ABT-418
Systematic (IUPAC) name
3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole
Identifiers
CAS Registry Number  N
PubChem CID:
ChemSpider  YesY
ChEMBL  YesY
Chemical data
Formula C9H14N2O
Molecular mass 166.22
 N   

ABT-418 is a drug developed by Abbott, that has nootropic, neuroprotective and anxiolytic effects,[1][2][3][4] and has been researched for treatment of both Alzheimer's disease[5] and ADHD.[6][7][8] It acts as an agonist at neural nicotinic acetylcholine receptors, subtype-selective binding with high affinity to the α4β2, α7/5-HT3, and α2β2 nicotinic acetylcholine receptors but not the α3β4 subtype[9][10] familiar to nicotine. ABT-418 was reasonably effective for both applications and fairly well tolerated, but produced some side effects, principally nausea, and it is unclear whether ABT-418 itself will proceed to clinical development or if another similar drug will be used instead.[11]

See also

References

  1. ^
  2. ^
  3. ^
  4. ^
  5. ^
  6. ^
  7. ^
  8. ^
  9. ^
  10. ^
  11. ^